Stay updated with breaking news from Junshi Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless
Investegate announcements from Junshi Biosciences, Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer
--6th approved indication of toripalimab in China, bringing more treatment options to patients with advanced NSCLCSHANGHAI, China, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd
-- Clinical trials of core drug candidates are progressing steadily with the debut of the company's FIH asset -- Toripalimab's sales performance is consistently improving; the US BLA is under review SHANGHAI
-- the 7th innovative drug in Junshi Biosciences' pipeline to get IND approval from the US FDASHANGHAI, China, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences"